Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasm, Residual × avelumab × Clear all

Phase

Status

Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 3 Triple Negative Breast Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Prostatic Neoplasms 2 Neoplasms 2 Head and Neck Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Merkel Cell 2 Stomach Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Penile Squamous Cell Carcinoma (PSCC) 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Metastatic Urothelial Cancer 1 Melanoma 1 Lymphatic Metastasis 1 Gestational Trophoblastic Neoplasias (GTN) 1 Endometrial Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 10 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Advanced Solid Tumor 1

Interventions

Cyclophosphamide 7 venetoclax 6 Azacitidine 6 fludarabine 5 Cytarabine 4 Blood Specimen Collection 4 daratumumab 3 blinatumomab 3 Daunorubicin 3 tislelizumab 2 fludarabine phosphate 2 Liquid Biopsy 2 Lenalidomide 2 Idarubicin 2 Gemtuzumab 2 Capecitabine 2 Busulfan 2 trastuzumab deruxtecan 1 thymoglobulin 1 tetrathiomolybdate 1 talquetamab 1 tagraxofusp 1 sugemalimab 1 sacituzumab govitecan 1 relugolix 1 pembrolizumab 1 pegaspargase 1 palbociclib 1 obinutuzumab 1 ivosidenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04841148 2025-03-11

PALAVY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡